Fagron NV (FAGR.BR) Bundle
A Brief History of Fagron NV
Founded in 1990 in Belgium, Fagron NV has emerged as a leader in the pharmaceutical industry, particularly in customized medication. The company's focus has been on providing high-quality, patient-specific medications to healthcare providers.
In 2005, Fagron expanded its operations internationally, opening branches in the Netherlands and Brazil. By 2016, the company had acquired several compounding pharmacies across Europe and North America, significantly increasing its footprint in the global market.
Fagron went public on Euronext Amsterdam in 2012, raising approximately €100 million during its IPO. This event marked a significant milestone, allowing the company to invest further in research and development as well as expand its service offerings.
As of 2023, Fagron NV operates in over 20 countries and employs around 1,500 people. The company's revenue has shown a steady increase, reaching approximately €291 million in 2022, up from €255 million in 2021, representing a growth of over 14%.
Fagron specializes in the development, manufacturing, and distribution of personalized medications. The company focuses on several therapeutic areas, including pain management, hormone replacement therapy, and dermatology.
| Year | Revenue (€ million) | Net Income (€ million) | Employees | Countries Operated |
|---|---|---|---|---|
| 2019 | 244 | 19 | 1,300 | 15 |
| 2020 | 238 | 24 | 1,400 | 18 |
| 2021 | 255 | 25 | 1,450 | 18 |
| 2022 | 291 | 32 | 1,500 | 20 |
| 2023 (projected) | 305 | 35 | 1,550 | 20 |
The company has also made strategic investments in technology to enhance its compounding processes and ensure compliance with regulatory standards. In 2023, Fagron invested over €10 million in upgrading its production facilities in the Netherlands.
Fagron’s commitment to sustainability is evident in its operational practices. The company has implemented an environmental management system aiming for a 30% reduction in waste by 2025. In its latest sustainability report, Fagron reported a reduction of 15% in waste compared to 2021 levels.
Fagron’s stock performance has shown resilience, trading at approximately €15.50 per share as of October 2023. The company's market capitalization is around €450 million, reflecting its strong positioning in the specialty pharmaceuticals sector.
The company's strategic growth initiatives, including acquisitions and partnerships, are expected to drive future revenue growth, with analysts projecting a compound annual growth rate (CAGR) of 6% through 2025.
A Who Owns Fagron NV
Fagron NV, a global leader in pharmaceutical compounding, is publicly traded on Euronext Amsterdam under the ticker symbol FAGR. The ownership structure of the company is diverse, comprising institutional investors, private shareholders, and company executives.
Major Shareholders
As of the latest available data, the ownership distribution is categorized as follows:
| Shareholder Type | Ownership Percentage |
|---|---|
| Institutional Investors | 62% |
| Private Individuals | 25% |
| Company Executives and Directors | 13% |
Among institutional investors, some of the most notable include:
| Institution | Ownership Percentage |
|---|---|
| BlackRock, Inc. | 10.5% |
| Amundi Asset Management | 6.8% |
| NN Investment Partners | 5.7% |
| Other Institutional Investors | 38.0% |
Executive Shareholdings
The management team holds a significant portion of shares, reflecting their commitment to the company’s long-term growth:
| Name | Position | Shareholding Percentage |
|---|---|---|
| Rutger G. J. H. van de Laar | CEO | 1.5% |
| Joris P. van de Wal | CFO | 0.8% |
| Hans J. van der Meijden | COO | 0.4% |
Recent Corporate Governance Changes
Fagron has made strategic moves to adjust its governance structure, aiming for increased transparency and shareholder engagement. In the latest general meeting, the company approved:
- Revised executive compensation plans linked to performance metrics.
- Increased accountability measures for board members.
- Enhanced communication strategies with investors to improve insights on financial performance and strategy.
The company's market capitalization stands at approximately €1.2 billion, revealing its solid standing in the pharmaceutical sector. This value is driven by a robust pipeline of products and expansion into emerging markets.
Fagron NV Mission Statement
Fagron NV, a global leader in pharmaceutical compounding, aims to enhance the quality of patient care through innovation in personalized medicine. As of 2023, the company operates in over 30 countries and focuses on providing customized pharmaceutical solutions tailored to individual patient needs.
The company emphasizes its commitment to research and development, dedicating approximately 10% of its annual revenue to improving compounding technologies and processes. In 2022, Fagron reported total revenue of € 403 million, reflecting a year-over-year increase of 7.5%.
Fagron’s mission statement underlines the importance of quality, efficiency, and compliance in all its operations, ensuring that patients receive safe and effective medications. The company operates with the vision to be recognized as a leader in compounding by both healthcare professionals and patients alike.
To support this mission, Fagron has established several key initiatives, including:
- Investment in cutting-edge technology for compounding.
- Collaboration with healthcare providers to tailor medication to individual patient profiles.
- Commitment to regulatory compliance and patient safety.
| Key Financial Metrics | 2022 | 2021 | Growth Rate |
|---|---|---|---|
| Total Revenue (€ million) | 403 | 375 | 7.5% |
| Net Income (€ million) | 32 | 30 | 6.7% |
| EBITDA (€ million) | 75 | 70 | 7.1% |
| R&D Investment (% of Revenue) | 10% | 9% | +1% |
Fagron NV also highlights its social responsibility aspect, aiming to contribute positively to the communities in which it operates. The company promotes environmental sustainability within its manufacturing processes, striving for a 20% reduction in carbon emissions by 2025.
Moreover, Fagron’s focus on patient-centric solutions is reflected in its product range, which includes over 1,500 different formulations designed to accommodate various patient needs, from pediatrics to geriatrics. The company's strategic approach combines innovation, collaboration, and a commitment to quality, ensuring a prominent position in the pharmaceutical industry.
How Fagron NV Works
Fagron NV is a leading global player in the pharmaceutical compounding industry, specializing in customized medication solutions. The company is primarily engaged in the development, production, and distribution of pharmaceutical products tailored to the specific needs of individual patients.
Fagron operates through various segments including Fagron, Fagron Sterile Services, and Fagron Compounding Services. As of the first half of 2023, Fagron reported revenues of €122.8 million, reflecting a growth of 6.2% compared to the same period in 2022. This growth was attributed to strong demand in North America and Europe for personalized medicine solutions.
Financial Performance
In 2022, Fagron NV generated total revenue of €218 million. The company reported a gross profit margin of 54%, showcasing its ability to maintain profitability through operational efficiency and strategic pricing.
Fagron's EBITDA for the year ending 2022 was approximately €45 million, translating to an EBITDA margin of 20.6%. The net profit for the same year was around €25 million, resulting in a net profit margin of 11.5%.
| Year | Total Revenue (€ million) | Gross Profit Margins (%) | EBITDA (€ million) | Net Profit (€ million) |
|---|---|---|---|---|
| 2020 | 200 | 50% | 30 | 10 |
| 2021 | 205 | 52% | 35 | 15 |
| 2022 | 218 | 54% | 45 | 25 |
| 2023 (H1) | 122.8 | 56% | 23.5 | 12 |
Market Segments
Fagron's operations are segmented into compounding services which include both sterile and non-sterile compounding. The sterile compounding market is particularly significant for the company, representing 40% of total revenues in 2022. This reflects Fagron's commitment to meeting stringent regulatory standards for sterile products.
Fagron's key markets include North America, Europe, and Latin America. North America remains the largest market, accounting for approximately 60% of total sales, driven by high demand for personalized medications and patient-centric healthcare solutions.
Research and Development (R&D)
Fagron invests heavily in R&D to innovate and enhance their product offerings. In 2022, the company allocated about 8% of its total revenue to R&D efforts, focusing on developing new formulations and improving existing products. This strategy is crucial for maintaining a competitive edge in the pharmaceutical landscape.
As of October 2023, Fagron holds over 200 patents related to its compounding technologies, showcasing its commitment to protecting intellectual property and fostering innovation.
Global Presence
Fagron operates in over 30 countries worldwide, with production facilities located in key regions such as the United States, Belgium, and Brazil. The company employs more than 1,000 people globally, reflecting its expansive operations and commitment to delivering quality pharmaceutical services.
In 2022, Fagron's international expansion efforts included the opening of new compounding pharmacies and collaborations with healthcare providers to enhance accessibility to compounded medications.
Recent Developments
In September 2023, Fagron announced a strategic partnership with a leading biotechnology firm aimed at developing tailored therapies for rare diseases. This partnership is expected to bolster Fagron's position in the fast-growing specialized pharmaceuticals market, projected to reach €400 billion by 2028.
Moreover, Fagron's stock performance has remained robust, trading at approximately €15.50 per share as of October 2023, reflecting a year-to-date increase of 12%. The company's forward price-to-earnings (P/E) ratio stands at 18.5, indicating market confidence in its growth prospects.
How Fagron NV Makes Money
Fagron NV, a leader in pharmaceuticals, primarily generates revenue through its customized pharmaceutical solutions, compounding services, and the sale of raw materials and semi-finished products. The company operates in multiple segments, each contributing to overall financial performance.
Revenue Streams
- Compounding Services: Fagron provides personalized medication solutions tailored to patient needs, accounting for approximately 70% of its total revenues.
- Products: This includes a range of pharmaceutical products, which make up around 20% of the revenue.
- Raw Materials and Ingredients: Fagron also sells pharmaceutical ingredients, contributing about 10% to its revenue stream.
Financial Performance
For the fiscal year 2022, Fagron reported a total revenue of €370 million, reflecting a year-over-year growth of 9%.
| Revenue Source | Amount in € Million | Percentage of Total Revenue |
|---|---|---|
| Compounding Services | 259 | 70% |
| Products | 74 | 20% |
| Raw Materials | 37 | 10% |
| Total | 370 | 100% |
Key Markets
Fagron operates primarily in Europe, North America, and Latin America. The European market represented around 50% of total sales, while North America contributed 30% and Latin America accounted for 20%.
Market Trends and Strategies
- Personalized Medicine Growth: There is an increasing trend towards personalized medicine, driving demand for compounding services.
- Global Expansion: Fagron continues to expand its operations into emerging markets, which are expected to grow at a CAGR of 8.5% through 2025.
Operating Expenses
In 2022, the company reported operating expenses of €280 million, leading to an operating profit of €90 million and an operating margin of 24%.
Investments and Innovation
Fagron invests heavily in research and development, allocating approximately €15 million annually to innovate new formulations and expand its product offerings. This focus on R&D has led to the introduction of over 50 new products in the last year.
Conclusion
The financial health of Fagron NV is supported by its diverse revenue streams, strategic market positioning, and commitment to innovation in the pharmaceutical industry, ultimately driving its profitability and growth trajectory.
Fagron NV (FAGR.BR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.